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AbsTrACT
Genetic testing for hereditary cancer predisposition has 
evolved rapidly in recent years with the discovery of 
new genes, but there is much debate over the clinical 
utility of testing genes for which there are currently 
limited data regarding the degree of associated cancer 
risk. to address the discrepancies that have arisen 
in the provision of these tests across the UK, the UK 
Cancer Genetics Group facilitated a 1-day workshop 
with representation from the majority of national 
Health service (nHs) clinical genetics services. Using a 
preworkshop survey followed by focused discussion of 
genes without prior majority agreement for inclusion, 
we achieved consensus for panels of cancer genes with 
sufficient evidence for clinical utility, to be adopted 
by all nHs genetics services. to support consistency in 
the delivery of these tests and advice given to families 
across the country, we also developed management 
proposals for individuals who are found to have 
pathogenic mutations in these genes. However, we fully 
acknowledge that the decision regarding what test is 
most appropriate for an individual family rests with the 
clinician, and will depend on factors including specific 
phenotypic features and the family structure.
bACkground
National Health Service (NHS) clinical genetics 
services have in recent years taken advantage 
of the discovery of new genes and emerging 
evidence for associated cancer predisposition to 
carry out more extensive genetic testing via cancer 
gene panels, aiming to provide information and 
tailored management for more families with a 
hereditary cancer predisposition. However, there 
is much debate over the utility of testing genes for 
which there exist limited data regarding impact 
on cancer risk,1 and the gradual evolution of these 
panels has led to discrepancies in the genes tested 
by different laboratories. This has resulted in 
differences between what is offered to patients, as 
well as difficulty in managing families where rela-
tives are located in different parts of the country. 
For example, a relative may find that testing for 
the gene identified in their family is not offered 
in their region, or may be given different advice 
about risk management from that given to a rela-
tive with the same genetic variant.
To address this, the UK Cancer Genetics Group 
(UK-CGG), supported by the UK Genetic Testing 
Network (UKGTN), facilitated a 1-day work-
shop to achieve consensus for panels of cancer 
genes with clear clinical utility, to be adopted by 
all NHS genetics services. In addition, consensus 
guidelines for the management of individuals with 
pathogenic variants in these genes were subse-
quently developed.
MeThods
scope
The workshop focused on panels of genes for 
breast cancer, ovarian cancer, colorectal cancer 
and polyposis. These were selected as the most 
commonly used panels and also those with the 
largest discrepancies regarding inclusion of genes.
Participants
Invitations were sent to the lead cancer clini-
cians at each of the 24 UK genetics services, and 
if unable to attend they were given the option 
to send a colleague in their place. All but two 
services were represented at the workshop. Also 
represented were clinical scientists from NHS 
genetics laboratories currently offering cancer 
panel tests, genetic counsellors with a specialist 
interest in cancer genetics, and representatives 
from UKGTN, UK-CGG and Genomics England.
Preworkshop survey
Lists of potential genes were compiled from 
panel tests currently on offer at both NHS and 
private laboratories. Workshop participants were 
surveyed for their opinions on the inclusion of 
each gene prior to the workshop, in order to 
focus discussion on genes where inclusion was 
most contentious. Genes were deemed to have 
majority agreement if >75% of participants said 
they should be included.
Presentation of evidence for and against 
inclusion of genes
Based on their survey responses, workshop partic-
ipants were asked to present either for or against 
the inclusion of genes with <75% prior agree-
ment. Those presenting in favour of inclusion 
were also asked to present management proposals 
for families where a pathogenic variant was iden-
tified (see online supplementary information 1).
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discussion groups
Participants were divided into three groups to discuss breast 
cancer, epithelial ovarian cancer and colorectal cancer/polyposis 
gene panels. Each group formulated a proposed panel based on 
the evidence presented, which was then presented to the full 
workshop, openly discussed and agreed. The focus of discussion 
was on the clinical utility of identifying pathogenic variants in 
each gene, but practical considerations of testing specific genes 
were also taken into account.
Meeting report
The agreed cancer panels were circulated to all attendees 
following the workshop and were presented at the UK-CGG 
Spring Meeting 2017 for further comment. The manuscript 
was also circulated to the attendees. It should be noted that this 
report is a summary of the workshop, and therefore does not 
necessarily represent the opinions of individual attendees or 
genetics services.
resulTs And disCussion
Preworkshop survey
Responses were received from 78% (25/32) of the clinicians and 
clinical scientists who were invited to complete the survey (see 
online supplementary information 2). The survey asked sepa-
rate questions about inclusion of genes on breast cancer, ovarian 
cancer, colorectal cancer and polyposis panels. The results for 
colorectal cancer and polyposis panels overlapped completely, 
reflecting the recognised overlap in phenotypes2 and indicating 
that this should be established as a single panel.
Genes with majority agreement (>75%) for each panel were 
as follows:
 ► breast cancer: BRCA1, BRCA2, PALB2, PTEN, STK11, TP53
 ► ovarian cancer: BRCA1, BRCA2, MLH1, MSH2, MSH6, 
PMS2, RAD51C, RAD51D
 ► colorectal cancer/polyposis: APC, MUTYH, SMAD4, 
BMPR1A, MLH1, MSH2, MSH6, PMS2, EPCAM (deletion 
of exons 8–9), POLE, POLD1, STK11.
genes included or excluded following presentation of 
evidence and discussion
Breast cancer panel
It was agreed to include ATM and CHEK2, which both confer a 
moderately increased risk of breast cancer,1 3 but concerns about 
the interpretation of results for these genes led to the recommen-
dation that only truncating variants should be reported,4 in addi-
tion to ATM c.7217T>G p.(Val2424Gly), which is recognised as 
conferring a higher risk of breast cancer.5 Insufficient evidence 
was found for a significant risk of breast cancer associated 
with NBN,6 BRIP17 or BARD1,6 so these were excluded from 
the panel. CDH1 was also excluded due to its relevance only 
in cases of lobular breast cancer, and the considerable difficulty 
presented by interpreting variants in families with no history of 
lobular breast cancer or diffuse gastric cancer.8 However, testing 
for CDH1 should be available for relevant cases and offered 
according to the current guidelines.9 It was noted that the inclu-
sion of SNPs associated with breast cancer risk10 will need to be 
considered in future, but will be more relevant to predicting risk 
in unaffected individuals rather than genetic testing of individ-
uals with cancer.11
Ovarian cancer panel
It was agreed to include BRIP1, which confers sufficient 
risk of ovarian cancer such that prophylactic bilateral 
salpingo-oophorectomy is considered.12 Insufficient evidence 
was found for a significant risk of ovarian cancer associated with 
the EPCAM deletion,13 TP5314 and also PMS2, which originally 
had majority agreement in the survey, but was excluded when 
new data were taken into account.15 STK11 was also excluded 
since mutations are associated only with a rare type of ovarian 
cancer—sex cord tumours with annular tubules—so testing on 
a gene panel primarily intended for individuals with epithelial 
ovarian cancer was not considered appropriate. For a review of 
genes to consider in rare non-epithelial ovarian neoplasms, see 
Foulkes et al.16
Colorectal cancer/polyposis panel
Only two genes did not secure majority agreement for inclu-
sion—GREM1 (upstream duplication) and NTHL1—although 
the survey results suggested respondents were unsure about 
these genes rather than that they disagreed with their inclusion. 
Following discussion it was agreed that both these genes could be 
included, but this should be optional since the GREM1 upstream 
duplication has to date only been reported in individuals with 
Ashkenazi Jewish ancestry, and the frequency of pathogenic 
mutations in NTHL1 is low.17
A summary of the agreed panels is given in table 1.
expected standard of analysis
It is expected that analysis will include sequencing of the coding 
region and intron/exon boundaries of each gene, except for 
EPCAM and GREM1, where only the common del/dup need 
be tested for. It is expected that copy number analysis to detect 
exonic deletions and duplications from sequencing data will 
be possible in the near future, but in the meantime this anal-
ysis should be carried out separately for the key genes BRCA1, 
BRCA2, APC, MLH1, MSH2, MSH6 and PMS2. For other genes, 
copy number analysis can be added where possible, but if not 
included this must be made clear on the report.
Management proposals
One of the key aims of this consultation was to improve consis-
tency of service delivery across the UK, and it was recognised 
that this extends to the management of individuals found to have 
pathogenic variants, as well as which genes are included on each 
panel. Although the level of evidence for some of the included 
Table 1 Agreed panels
breast cancer ovarian cancer
Colorectal cancer/
polyposis
ATM*
BRCA1
BRCA2
CHEK2†
PALB2
PTEN
STK11
TP53
BRCA1
BRCA2
BRIP1
MLH1
MSH2
MSH6
RAD51C
RAD51D
APC
BMPR1A
EPCAM (del exons 8–9)
GREM1 (upstream dup)‡
MLH1
MSH2
MSH6
MUTYH
NTHL1‡
PMS2
POLE
POLD1
PTEN
SMAD4
STK11
*Truncating variants plus ATM c.7271T>G, p.(Val2424Gly).
†Truncating variants.
‡Optional.
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genes makes the establishment of firm guidelines challenging, 
it was agreed that pragmatic management proposals would 
be of benefit to the UK cancer genetics community. These are 
summarised in table 2.
ConClusion
Consensus was achieved at the workshop for genes to be 
included on panel tests for breast cancer, ovarian cancer and 
colorectal cancer/polyposis. Clinical entry points and testing 
criteria have not been addressed here since these are currently 
being developed by NHS England. It was recognised that when 
resources are limited there is a tension between investing in 
panel tests as opposed to testing a smaller number of genes 
with wider testing criteria. However, the cost of panel testing 
is dropping rapidly so that in the near future it will likely 
become more efficient to carry out panel testing on all patients 
with selective analysis of genes according to testing indica-
tion. From a technical point of view, this will be most expe-
dient when panel tests can reliably detect all large (exonic) 
deletions and duplications as well as sequence variants. It 
was also recognised that access to and funding for panel tests 
currently vary across the UK, but it is hoped that one of the 
outcomes of this consultation will be improved consistency, 
providing centres with a standard of testing to work towards. 
However, this aim for consistency is not intended to over-
ride a clinician’s choice to target specific genes they consider 
Table 2 Management proposals.
breast cancer genes
gene breast cancer risk management references
ATM*† 12–18 monthly mammography from 40 to 50 depending on family 
history, then NHSBSP
For c.7271T>G consider BRCA-equivalent
Ataxia-telangiectasia in children: guidance on diagnosis and 
clinical care18
Protocols for the surveillance of women at higher risk of 
developing breast cancer, Public Health England19
BRCA1 As per national guidelines NICE CG16420
BRCA2 As per national guidelines NICE CG16420
CHEK2†‡ 12-monthly mammography from 40 to 50, then NHSBSP
For homozygotes consider BRCA-equivalent
Tung et al21
PALB2† Consider BRCA-equivalent Tung et al21
PTEN§ Consider BRCA-equivalent UK-CGG guidelines for management of tumour risk in PTEN 
hamartoma syndrome22
STK11 Consider BRCA-equivalent Beggs et al23
TP53 As per national guidelines NICE CG16420
ovarian cancer genes
gene ovarian cancer risk management references
BRCA1 As per national guidelines NICE CG16420
BRCA2 As per national guidelines NICE CG16420
BRIP1 Consider BSO at 45–50 years (and once family complete) Tung et al21
MLH1 Consider TAH and BSO from 40 years (and once family complete) Vasen et al25 and Daly et al26
MSH2 Consider TAH and BSO from 40 years (and once family complete) Vasen et al25 and Daly et al26
MSH6 Consider TAH and BSO from 40 years (and once family complete) Vasen et al25 and Daly et al26
RAD51C Consider BSO at 45–50 years (and once family complete) Tung et al21 and Daly et al26
RAD51D Consider BSO at 45–50 years (and once family complete) Tung et al21 and Daly et al26
Colorectal cancer/polyposis genes
syndrome Cancer risk management references
Lynch syndrome
Adenomatous polyposis syndromes
Peutz-Jeghers syndrome
Juvenile polyposis syndrome
PTEN-hamartomatous tumour syndromes
See International and European guidance as advised by InSiGHT, 
plus UK guidance on endoscopic colorectal surveillance issued by the 
British Society of Gastroenterology (due for revision).
Guidance on management of Lynch syndrome should be interpreted 
in the light of gene, gender, age and cancer history, as shown by the 
Prospective Lynch Syndrome Database at http://www.lscarisk.org/.
The reference databases for interpretation of variants in MSH2, 
MLH1, MSH6, PMS2, EPCAM, APC, MUTYH, POLD1, POLE and STK11 
are provided at http://www.insight-database.org/genes.
As listed under individual condition headings at  https://www.
insight-group.org/, including the following:
Vasen et al27
Cairns et al28
Vasen et al25
Møller et al15 29
*The Ataxia Telangiectasia guidelines recommend 18-monthly mammography, but where ATM pathogenic variants are identified in the context of a significant family history 
of breast cancer it is reasonable to offer annual mammography, bringing this into line with CHEK2 mutation carriers who have a similar risk. The guidelines do not give specific 
recommendations for the c.7271T>G variant so this is pragmatic, based on the evidence indicating this variant confers a much higher risk.
†For ATM, CHEK2 and PALB2 consider using BOADICEA to guide risk management.24
‡These recommendations include mammography and/or breast MRI. Given that the risk for CHEK2 c.1100delC is well defined, it is reasonable to offer mammography rather than 
MRI. There is much weaker evidence for other CHEK2 variants, but it seems reasonable to use the same protocol for these until further data emerge.
§These recommendations include mammography and/or breast MRI. As there is good evidence that the PALB2 risk is influenced by other factors such as family history, it would 
be reasonable to offer BRCA-equivalent surveillance to those women ascertained via family history clinics (where there is a strong family history) but to consider less intense 
surveillance in those women with no significant family history (eg, an incidental finding).
BOADICEA, Breast  and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm; BSO, bilateral salpingo-oophorectomy; NHSBSP, National Health Service Breast 
Screening Programme; NICE,  National Institute for Health and Care Excellence;  TAH, total abdominal hysterectomy; UK-CGG, UK Cancer Genetics Group. 
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most relevant to a particular family rather than offering a gene 
panel in every case.
One factor clinicians will take into account is that testing a 
larger number of genes will result in finding more variants of 
uncertain significance, which carries a cost in the time spent 
interpreting and explaining the results, and can leave families 
with more questions than answers. It is essential that these 
are collated centrally so that a shared understanding of their 
significance can be reached more rapidly and consistent infor-
mation is conveyed to families. It is because of the current 
challenges in interpreting variants of uncertain significance 
that at present we have recommended the reporting of only 
truncating variants in ATM and CHEK2. However, as these 
genes become better understood, it will no doubt emerge that 
some missense variants also confer an increased risk of breast 
cancer, and it is possible that some could be higher penetrance 
alleles similar to ATM c.7271T>G.
Another factor is that particularly in breast cancer fami-
lies, finding a pathogenic variant in a moderate risk gene in 
the context of a high-risk family history does not always aid 
clinical management, since the variant cannot be assumed to 
account for all of the genetic risks in the family. Hence offering 
testing to unaffected close relatives may not be informative in 
helping to advise them about their level of risk and guide deci-
sion-making around risk management. However, these variants 
can be used to identify more distantly related individuals (eg, 
those related via intervening unaffected women) who are at 
moderately increased risk and would not have previously been 
eligible for additional breast screening. Therefore the decision 
about whether to offer panel testing will often depend on the 
family structure and whether there are unaffected individuals 
to whom the information will be relevant.
It is important to note that this is a rapidly evolving field, 
and these recommendations will need to be revisited as further 
evidence emerges for inherited cancer risk. We plan to review 
the gene lists annually, and any updates will be posted on the 
UK-CGG website (http://www. ukcgg. org). In particular, the 
advent of routine tumour sequencing in cancer diagnosis and 
the move to whole genome sequencing and interrogation of 
virtual panels will change the contexts and capabilities of germ-
line panel testing. As the technological barriers in sequencing 
are largely overcome, the importance of testing genes only 
where there is rigorous clinical evidence will become ever 
more critical.
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